Related references
Note: Only part of the references are listed.New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis
J. C. Crockett et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content
Salvatore Pece et al.
CELL (2010)
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison T. Stopeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Eva Gonzalez-Suarez et al.
NATURE (2010)
Control of mammary stem cell function by steroid hormone signalling
Marie-Liesse Asselin-Labat et al.
NATURE (2010)
Progesterone induces adult mammary stem cell expansion
Purna A. Joshi et al.
NATURE (2010)
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Daniel Schramek et al.
NATURE (2010)
An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases
Eduardo Maldonado-Gonzales et al.
WIENER MEDIZINISCHE WOCHENSCHRIFT (2010)
Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
Karim Fizazi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Central control of fever and female body temperature by RANKL/RANK
Reiko Hanada et al.
NATURE (2009)
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations
Matteo M. Guerrini et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
GATA-3 and the regulation of the mammary luminal cell fate
Hosein Kouros-Mehr et al.
CURRENT OPINION IN CELL BIOLOGY (2008)
Central control of thermogenesis in mammals
Shaun F. Morrison et al.
EXPERIMENTAL PHYSIOLOGY (2008)
The cytokine RANKL produced by positively selected thymocytes Fosters medullary thymic epithelial cells that express autoimmune regulator
Yu Hikosaka et al.
IMMUNITY (2008)
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance
Taishin Akiyama et al.
IMMUNITY (2008)
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer
Georgiana K. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The role of exercise and PGC1α in inflammation and chronic disease
Christoph Handschin et al.
NATURE (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone Metastases
Allan Lipton et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
Cristina Sobacchi et al.
NATURE GENETICS (2007)
RANK signals from CD4+3- inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla
Simona W. Rossi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin
Jun-Li Luo et al.
NATURE (2007)
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Hiroshi Takayanagi
NATURE REVIEWS IMMUNOLOGY (2007)
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells
Karin Loser et al.
NATURE MEDICINE (2006)
The RANK/RANKL/OPG triad in cancer-induced bone diseases
William C. Dougall et al.
CANCER AND METASTASIS REVIEWS (2006)
Regulation of cancer cell migration and bone metastasis by RANKL
DH Jones et al.
NATURE (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Receptor activator of NF-κB ligand regulates the proliferation of mammary epithelial cells via Id2
NS Kim et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Breast cancer metastasis: Markers and models
B Weigelt et al.
NATURE REVIEWS CANCER (2005)
Cytokines, PGE2 and endotoxic fever:: a re-assessment
CM Blatteis et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2005)
Idiopathic hyperphosphatasia and TNFRSF11B mutations:: Relationships between phenotype and genotype
B Chong et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Receptor activator of NF-κB ligand induction via Jak2 and Stat5a in mammary epithelial cells
S Srivastava et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Genetic regulation of osteoclast development and function
SL Teitelbaum et al.
NATURE REVIEWS GENETICS (2003)
Transcriptional regulators in mammary gland development and cancer
JE Visvader et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2003)
Osteoclast differentiation and activation
WJ Boyle et al.
NATURE (2003)
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype
T Cundy et al.
HUMAN MOLECULAR GENETICS (2002)
Metastasis to bone: Causes, consequences and therapeutic opportunities
GR Mundy
NATURE REVIEWS CANCER (2002)
Reaching a genetic and molecular understanding of skeletal development
G Karsenty et al.
DEVELOPMENTAL CELL (2002)
Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis
MP Whyte et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
IKKα provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development
YX Cao et al.
CELL (2001)
The role of fever in the infected host
JD Hasday et al.
MICROBES AND INFECTION (2000)
Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE
D Kim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
JE Fata et al.
CELL (2000)
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
J Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Therapeutic approaches to bone diseases
GA Rodan et al.
SCIENCE (2000)
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
AE Hughes et al.
NATURE GENETICS (2000)
Share Paper
